MYH7 and heart failure: It has been shown that Omecamtiv mecarbil (OM), a selective small-molecule activator of cardiac myosin (MYH7) that was initially developed as a treatment for heart failure [67, 82], increases submaximal force production in type 1 skeletal muscles of Neb cKO mouse model [48] and rat diaphragm [56].